Jaguar8 commented on a stock · Aug 13, 2024 21:19

NEWS

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals (Nasdaq: NRBO) has completed enrollment for Part 1 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog agonist for obesity treatment. The single ascending dose (SAD) study enrolled 45 participants across 5 cohorts. No significant issues were encountered, allowing an accelerated start to the multiple ascending dose (MAD) Part 2.
Key points:
Top-line data from SAD Part 1 expected in Q3 2024
MAD Part 2 results anticipated in Q1 2025
Pre-clinical data showed superior weight loss compared to semaglutide and tirzepatide
DA-1726 may become a best-in-class obesity drug with better tolerability
Part 3 of the trial planned to start in Q3 2025, with interim data expected mid-2026 and top-line results in H2 2026

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

2506 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

8162

Followers

Following

93K

Visitors